Status:
COMPLETED
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
Lead Sponsor:
Bial - Portela C S.A.
Conditions:
Partial Epilepsy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy subjects
- Aged 18-55 years
- Body mass index (18.5-29 kg/m3)
Exclusion
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00900237
Start Date
November 1 2008
End Date
February 1 2009
Last Update
December 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS LSS Clinical Pharmacology Unit Antwerpen
Antwerp, Belgium, B-2060